Author

Haotian Wang

Chinese Academy of Sciences

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Research Focus:metabolism & bioenergetics· 1 Research Focus:protein structure prediction· 1

Frequent Co-Authors

Chao ShangiD· 1 shared Congwen WeiiD· 1 shared Guanying ZhangiD· 1 shared Haiwen Lin· 1 shared Hongguang ReniD· 1 shared Jiafan YuaniD· 1 shared Jin Han· 1 shared Jingyi WangiD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBioengineering

Chao ShangORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

mTORC1 Directs TNF-Induced Life-or-Death Decisions via Complex I Destabilization

Zhao Deng, Jingyi Wang, Zhao Deng, Kai Yu, Yan Liu, Kai Yu, Haiwen Lin, Jiafan Yuan, Tingyun Yang, Haotian Wang, T T Yang, Youwei Ai

This paper shows mTORC1 regulates TNF-induced cell death by destabilizing complex I and promoting complex II formation, with implications for disease therapies.

bioRxiv · Jun 29, 2026 · PreprintCell Biology

Conversion of a Viral Glycan Shield into a Binding Anchor via Causal-Driven Antibody Optimization

X T Wang, Guanying Zhang, Mingda Hu, Jin Han, Chao Shang, Lejin Zhang, Zhengshan Chen, Ping Huang, Wentao Wang, Xinru Zhao, Yunzhu Dong, Yunxiang Zhao, Peng Lv, Xiaodong Zai, R H Jin, , Xiangyang Chi

This paper develops AENCS to engineer antibodies targeting glycosylated epitopes, demonstrating ACC01's 24-fold improved neutralization against SARS-CoV-2 variants.

bioRxiv · Jun 26, 2026 · PreprintBioengineering